SCHEMBL3908131

SCHEMBL3908131

CC(=O)N1CCN(Cc2ccccc2)C(=O)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.55
CYP46A1 Q9Y6A2 1/20 0.53
CYP2D6 P10635 3/20 0.51
POLB P06746 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 1/20 0.51
PRMT5 O14744 1/20 0.51
WDR77 Q9BQA1 1/20 0.51
DPP4 P27487 2/20 0.51
HRH3 Q9Y5N1 2/20 0.50
USP19 O94966 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TACR1 P25103 1/20 0.47
CACNA1G O43497 1/20 0.46
CACNA1H O95180 1/20 0.46
CACNA1I Q9P0X4 1/20 0.46
PARP1 P09874 1/20 0.45
PARP2 Q9UGN5 1/20 0.45
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4108176 0.88 KMT2A (0.54) BRD4CYP46A1CYP2D6POLBCYP2C9
SCHEMBL3911313 0.85 DPP4 (0.55) POLBDPP4HRH3ALDH1A1GAA
SCHEMBL3913750 0.84 FAAH (0.46) BRD4CYP46A1PRMT5WDR77DPP4
SCHEMBL1049753 0.81 HDAC1 (0.50) CYP46A1CYP2D6POLBCYP2C9CYP2C19
SCHEMBL3906556 0.81 FAAH (0.49) BRD4CYP46A1CYP2C9KMT2APRMT5
SCHEMBL3902852 0.80 SMN1; SMN2 (0.56) CYP46A1CYP2D6POLBCYP2C9CYP2C19
SCHEMBL30835503 0.78 HRH3 (0.53) CYP46A1CYP2D6POLBCYP2C9CYP2C19
SCHEMBL14107100 0.78 L3MBTL1 (0.48) BRD4CYP46A1CYP2D6POLBCYP2C9
SCHEMBL12361201 0.78 L3MBTL1 (0.54) BRD4CYP2D6POLBCYP2C9CYP2C19
SCHEMBL13497575 0.77 DPP4 (0.50) CYP46A1CYP2D6POLBCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7517532-B2 Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2009-04-14 US disclosed
US-7517532-B2 Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2009-04-14 US disclosed
US-7517532-B2 Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2009-04-14 US disclosed
US-7399763-B2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-07-15 US disclosed
EP-1549315-A4 DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2007-05-23 EP disclosed
US-20060024330-A1 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2006-02-02 US disclosed
EP-1549315-A2 DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2005-07-06 EP disclosed
WO-2004024078-A2 DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2004-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060024330-A1 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors DHPS, DUT, CDKN1A BRD4 1733/4885CYP46A1 2440/4885CYP2D6 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.